Charles Gibson
Interventional Cardiology · Boston, MANPI 1124053277
Payments from drug & device makers
Across 329 payments — averaging $49,407 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$15.4M
- Janssen Research & Development, LLC$200K
- Janssen Scientific Affairs, LLC$197K
- Avertix Medical, Inc$60K
- Amgen$48K
- Daiichi Sankyo Inc.$46K
- plus $324K from 28 others
Across 5 payments — averaging $5511.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amarin Pharma, Inc.$28K
- Novo Nordisk AS$55
What the payments were for
- Consulting fees$540,56782%
- Speaking & faculty fees$57,2989%
- Travel & lodging$48,1667%
- Food & beverage$6,7791%
- Education$7,8001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 93 | $15,379,787 |
| Janssen Research & Development, LLC | 23 | $200,018 |
| Janssen Scientific Affairs, LLC | 31 | $196,694 |
| Avertix Medical, Inc | 2 | $60,000 |
| Amgen | 20 | $47,687 |
| Daiichi Sankyo Inc. | 7 | $46,282 |
| Boston Scientific | 25 | $38,361 |
| Amarin Pharma, Inc. | 27 | $38,201 |
| Heartflow, Inc. | 11 | $29,347 |
| E.r. Squibb & Sons, L.L.C. | 5 | $26,150 |
| Intercept Pharmaceuticals, Inc. | 4 | $23,800 |
| Chiesi USA, Inc. | 1 | $21,840 |
| Roche Diagnostics International Ltd | 6 | $16,226 |
| AMAG Pharmaceuticals, Inc. | 8 | $15,776 |
| Janssen Global Services, LLC | 10 | $15,403 |
| Merck | 11 | $14,819 |
| Johnson & Johnson | 5 | $13,517 |
| Cardiva Medical, Inc. | 6 | $10,990 |
| Haemonetics Corporation | 6 | $9,956 |
| Portola Pharmaceuticals, LLC | 1 | $8,731 |
| Novartis | 3 | $8,712 |
| Pfizer | 4 | $7,540 |
| Alnylam Pharmaceuticals Inc. | 1 | $5,250 |
| Genentech, Inc. | 2 | $4,799 |
| F. Hoffmann-la Roche AG | 1 | $3,220 |
| Esperion Therapeutics, Inc. | 5 | $3,164 |
| Bayer | 1 | $3,000 |
| Novo Nordisk | 2 | $2,322 |
| Boehringer Ingelheim International GmbH | 1 | $1,480 |
| AstraZeneca | 1 | $1,074 |
| Novo Nordisk AS | 3 | $640 |
| Medtronic | 1 | $35 |
| Celonova Biosciences, Inc. | 1 | $25 |
| Siemens Medical Solutions USA, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$69,051
- Savaysa$46,282
- Vascepa$37,811
- FFRct$29,293
- KENGREAL$21,840
- WATCHMAN FLX$19,013
- EVENITY$15,200
- FERAHEME$12,384
- Repatha$11,717
- WATCHMAN Access System$11,008
- MAKENA$10,740
- INTRAROSA$10,740
- Watchman$7,500
- TEG$5,769
- TNKase$4,720
- TEG6s HEMOSTASIS SYSTEM$4,154
- LEQVIO$3,960
- NEXLETOL$3,137
- CELEBREX$2,520
- PAXLOVID$2,500
How this compares
$16,254,871 in reported general payments places this provider in the 95th percentile of 128 interventional cardiology providers in Massachusetts.
See all interventional cardiology providers in Massachusetts →
Other interventional cardiology in Boston
- Eric SecemskyBoston$7.3M
- Duane PintoBoston$4.2M
- Suzanne BaronBoston$3.9M
- Pinak ShahBoston$3M
- Robert YehBoston$2.1M
- Jeffrey PopmaBoston$1.9M
- Roger LahamBoston$1.2M
- Farouc JafferBoston$900K
- Darshan DoshiBoston$838K
- Nicola MaschiettoBoston$540K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.